In a recent series, 14 CGD patients with refractory inflammation involving the GI, pulmonary, cutaneous and/or genitourinary systems were treated with anti-TNFα therapy for a median duration of 1.9 years (5). This evidence concerns the gene TNF and chronic granulomatous disease.